preclinics discovery
preclinics discovery is a subsidiary of preclinics GmbH. As a contract research and development organisation (CRDO), we take on development projects for our clients and develop our own technology platforms, which partners can use and license. Our work is supported by the preclinical and bioanalytical expertise of preclinics.
Ongoing projects
Botulinum neurotoxin, delivered as a nucleic acid
BoNT encoded as mRNA or DNA, aiming for a longer-lasting effect and an improved safety profile.
Depot formulations for mRNA transfection
Formulations designed to extend mRNA expression while lowering toxicity.
Gentle treatment of larger skin areas
Needle-free microinjection for pain-free treatment of larger skin areas.
Strong antibody responses to difficult antigens
VacciTag™ uses pre-existing tetanus immunity to generate high antibody titers without harsh, toxic adjuvants.
Interested in a platform or a development project?
Talk to us about licensing one of our platforms or developing your own therapeutic concept. We will discuss feasibility, study design and next steps with you.
- Wetzlarer Str. 20, 14482 Potsdam, Germany
- +49 (0) 331 243433-50
- info@preclinics-discovery.com
